Literature DB >> 7519977

Buprenorphine: duration of blockade of effects of intramuscular hydromorphone.

M I Rosen1, E A Wallace, T J McMahon, H R Pearsall, S W Woods, L H Price, T R Kosten.   

Abstract

Six opioid-dependent in-patients were maintained on daily sublingual doses of buprenorphine at 2, 6, and 12 mg/day for five days at each dose in a randomized, balanced sequence. Placebo buprenorphine was substituted for the next three days, and challenge doses of the mu agonist hydromorphone were administered on the three days. Planned comparisons in a 3-factor ANOVA showed dose-dependent hydromorphone effects, significant blockade of 'high' by the 12 mg buprenorphine dose, and no differences on hydromorphone-induced 'high' across 72 h of active buprenorphine. The data suggest that the blockade by buprenorphine of 'high' persists for at least 72 h after the last dose of buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519977     DOI: 10.1016/0376-8716(94)90121-x

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.

Authors:  Azmi F Nasser; Mark K Greenwald; Bradley Vince; Paul J Fudala; Philip Twumasi-Ankrah; Yongzhen Liu; J P Jones; Christian Heidbreder
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

2.  Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.

Authors:  Andrew S Huhn; Eric C Strain; George E Bigelow; Michael T Smith; Robert R Edwards; D Andrew Tompkins
Journal:  Anesthesiology       Date:  2019-01       Impact factor: 7.892

Review 3.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

Review 4.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

6.  Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate.

Authors:  Amelia Avachat; Vikram Kotwal
Journal:  AAPS PharmSciTech       Date:  2007-10-19       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.